Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (23713)	5/21/2007 3:31:52 PM
From: Arthur Radley	Read Replies (1) of 52153

When the lawyers get this one to trial, statements from Glaxo like this one will surely not make friends with the jury. Seems that Glaxo is admitting, that sure...30% of you might die or have a heart attack and if you happen not to be in this 30% group you will not suffered any adverse events, therefore, there is no problem with our drug. yahoo.reuters.com A study published in the New England Journal of Medicine said Avandia increased cardiac-related deaths and heart attacks. Dr. Robert Meyer, head of the FDA office that reviews diabetes drugs, said other data contradicted those findings. "FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies," Meyer told reporters during a conference call. "Further, the FDA does not know whether the other approved treatments in the same class of drugs ... have less, the same, or other greater such risks," he said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next